On Thursday, Sanofi SA (ADR) (NYSE:SNY)’s shares inclined 0.16% to $49.77.
Sanofi (SAN) and the life sciences team at Google declared recently that they are collaborating to improve care and outcomes for people with type 1 and type 2 diabetes. The partnership will pair Sanofi’s leadership in diabetes treatments and devices with Google’s expertise in analytics, miniaturized electronics and low power chip design. The companies will explore how to improve diabetes care by developing new tools that bring together many of the formerly siloed pieces of diabetes administration and enable new kinds of interventions. This comprises health indicators such as blood glucose and hemoglobin A1c levels, patient-stated information, medication regimens and sensor devices.
Sanofi and the life sciences team at Google will combine their respective expertise in science and technology to work on better ways to collect, analyze and understand multiple sources of information impacting diabetes. The hope is that it will be easier for patients to successfully manage their diabetes, which would reduce the risk of complications, improve outcomes and ultimately lower costs.
Results of this analysis were presented recently at the ESC Congress 2015 in London, and the 78 week results from two of the four trials comprised of in the analysis, ODYSSEY FH I and II, were co presently published online in the European Heart Journal.
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, counting Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, in addition to Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, in addition to provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-as compared to-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer.
Christopher & Banks Corporation (NYSE:CBK)’s shares dropped -13.75% to $1.38.
Christopher & Banks Corporation (CBK), a specialty women’s apparel retailer, recently stated results for the thirteen week period ended August 1, 2015.
Results for the Thirteen Week Period Ended August 1, 2015
- Net sales totaled $94.0 million, as contrast to $106.6 million for the thirteen weeks ended August 2, 2014. During the quarter, the Company operated an average of 4.4% fewer stores than during the comparable period last year, reflecting its MPW store conversion strategy; offset to some extent by new store openings, primarily outlets.
- Same-store sales reduced 12.4% in the thirteen weeks ended August 1, 2015, as contrast to the thirteen weeks ended August 2, 2014; this follows a 4.7% same-store sales enhance in last year’s second quarter.
- Gross margin was 32.9% contrast to 35.3% in the second quarter of fiscal 2014.
- Operating loss was $1.7 million for the thirteen week period ended August 1, 2015. This compares to operating income of $3.3 million in the second quarter of fiscal 2014.
- Net loss totaled $0.7 million, or ($0.02) per share. Net income for the thirteen weeks ended August 2, 2014 totaled $3.4 million, or $0.09 per diluted share.
Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of women’s apparel and accessories in the United States. The company designs, sources, and sells women’s apparel and accessories to customers ranging in age from 45 to 60. Its stores offer women’s apparel comprising of knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrics, leisure wear, and dresses in missy, petite, and women sizes, in addition to jewelry and accessories.
At the end of Thursday’s trade, Kilroy Realty Corp (NYSE:KRC)‘s shares surged 0.58% to $64.13.
Kilroy Realty Corporation (KRC) declared that its operating partnership, Kilroy Realty, L.P., has priced an underwritten public offering of $400 million aggregate principal amount of its 4.375% senior unsecured notes due 2025 (the “Notes”). The Notes will pay interest semi-annually at a rate of 4.375% per annum and mature on October 1, 2025. The Notes were priced at 99.444% of the principal amount. The offering is predictable to close on September 16, 2015, subject to customary closing conditions. BofA Merrill Lynch, Barclays, J.P. Morgan and Wells Fargo Securities acted as joint book-running managers.
Net proceeds from the offering will be about $394.5 million, after deducting underwriting discounts and our estimated expenses. We intend to use the net proceeds from the offering to refinance the operating partnership’s 5.0% senior notes due 2015 and for general corporate purposes, which may comprise acquiring land and properties, funding development projects and repaying other outstanding indebtedness. Pending application of the net proceeds for those purposes, we may use the net proceeds from the offering to repay borrowings under the operating partnership’s revolving credit facility and/or temporarily invest such net proceeds in marketable securities.
Kilroy Realty Corporation is a privately owned real estate investment trust. The firm engages in investment, development, and administration of properties. It invests in the real estate markets of Southern California. The firm portfolio comprises office, industrial, R&D, and multi-purpose properties. The company was founded in 1947 and is based in Los Angeles, California.
Omnicom Group Inc. (NYSE:OMC), ended its Thursday’s trading session with 0.51% gain, and closed at $67.40.
The DAS Group of Companies, a division of Omnicom Group Inc. (OMC) , FleishmanHillard has designated Magdalene Lee as General Manager of FleishmanHillard’s Malaysia office. An award-winning marketing and communications professional, Lee brings noteworthyintegrated communications expertise to the agency.
Lee is known best for her work across fast-moving consumer goods, finance, automotive and hospitality sectors. She possesses deep local-market knowledge and expertise in social media administration, crisis and issues communications, brand marketing and reputation administration campaigns. In her new leadership role for FleishmanHillard’s Kuala Lumpur operations, she will be focused on building its track record for highly effective, fully integrated campaigns combining public relations, brand marketing, social and digital across media platforms.
Lee has won numerous regional and local awards for agency leadership, creativity and growth. She joins FleishmanHillard from ARC Worldwide, a division of Leo Burnett. Her background comprises in-house, agency and business development roles.
Omnicom Group Inc., together with its auxiliaries, operates as an advertising, marketing, and corporate communications services company in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It offers services in advertising, customer relationship administration, public relations, and specialty communications areas. The company’s services comprise advertising, investor relations, brand consultancy, marketing research, content marketing, media planning and buying, corporate social responsibility consulting, mobile marketing, crisis communications, multi-cultural marketing, custom publishing, non-profit marketing, data analytics, organizational communications, database administration, package design, direct marketing, product placement, entertainment marketing, and promotional marketing services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
